Pemigatinib Demonstrates Activity in Previously Treated Soli

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

Related Keywords

Black Diamond , Texas , United States , Hebron , Israel General , Israel , Houston , Nuvation Bio , Pemigatinib Pemazyre , Hutchison Medipharma , Yingli Pharma , Chinese University Of Hong Kong , Amgen , Pfizer , Department Of Investigational Cancer Therapeutics , Novartis , Foundation Medicine Inc , University Of Texas Md Anderson Cancer Center , Pharma Group , Spectrum Pharmaceuticals , Debiopharm Group , Glaxosmithkline , Division Of Cancer Medicine , Hebron Institute Of Oncology , Jordi Rod , Investigational Cancer Therapeutics , Cancer Medicine , Cancer Center , Response Assessment , Foundation Medicine , Ellipses Pharma , Monte Rosa Therapeutics , Oncology One , Sardona Therapeutics , Hebron Institute , Avoro Capital Advisors , Boxer Capital , Chinese University , Hong Kong , Clarion Healthcare , Columbus Venture Partners , Envision Pharma Group , Tang Advisors , Black Diamond Therapeutics , Blueprint Medicines , Merck Sharp , Bicycle Therapeutics , Biomed Valley Discoveries , Cellestia Biotech , Cytomx Therapeutics , Linnaeus Therapeutics , Mirati Therapeutics , Taiho Pharmaceutical , Pemigatinib , Previously Treated Patients With Advanced Metastatic Or Unresectable Solid Tumors , Activating Fgfr Mutations Or Fusions Rearrangements , Cholangiocarcinoma , Central Nervous System Tumors , Gynecologic Tumors , Pancreatic Cancer , Fight 207 Trial , Nct03822117 , Eudract 2018 004768 69 , Jordi Rodón , D , Phd , The University Of Texas Md Anderson Cancer Center ,